Mode
Text Size
Log in / Sign up
N/A N=105 Randomized Treatment

Behavioral Weight Loss and Stigma Reduction

Obesity

Enrolled (actual)
105
Serious AEs
0.0%
Results posted
Oct 2022
Primary outcome: Primary: Percent Weight Change at Week 72 — -7.16; -5.19 percent weight change — p=0.14

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Stigma-Reduction Intervention (Behavioral); Behavioral Weight Loss (BWL) (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Pennsylvania
Primary completion
Jul 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent Weight Change at Week 72
-7.16; -5.19 0.14
SECONDARY
Loss of 5% or Greater of Initial Body Weight at Week 72
20; 21 0.89
SECONDARY
Loss of 10% or Greater of Initial Body Weight at Week 72
14; 7 0.06
SECONDARY
Percent Weight Change at Week 46
-8.2; -5.9 0.07
SECONDARY
Percent Weight Change at Week 20
-6.7; -5.7 0.42
SECONDARY
Loss of 5% or Greater of Initial Body Weight at Week 46
28; 22 0.24
SECONDARY
Loss of 10% or Greater of Initial Body Weight at Week 46
15; 9 0.24
SECONDARY
Loss of 5% or Greater of Initial Body Weight at Week 20
31; 22 0.07
SECONDARY
Loss of 10% or Greater of Initial Body Weight at Week 20
11; 5 0.21
SECONDARY
Change in Minutes of Physical Activity (Accelerometer) at Week 72
9.6; 7.2; 9.4; 8.4; 3.2; -10.2 0.62
SECONDARY
Change in Minutes of Physical Activity (Accelerometer) at Week 46
9.5; 5.4; 9.9; 10.5; 0.6; -17.9 0.46
SECONDARY
Change in Minutes of Physical Activity (Accelerometer) at Week 20
11.4; 8.8; 10.5; 9.9; 10.6; 4.7 0.63
SECONDARY
Change in Energy Expenditure at Week 72
314.8; 307.5 0.84
SECONDARY
Change in Energy Expenditure at Week 46
148.7; 260.4 0.53
SECONDARY
Change in Energy Expenditure at Week 20
452.5; 289.3 0.27
SECONDARY
Change in Exercise Self-efficacy at Week 72
-9.4; -15.0 0.22
SECONDARY
Change in Exercise Self-efficacy at Week 46
-10.6; -15.9 0.24
SECONDARY
Change in Exercise Self-efficacy at Week 20
1.1; -2.0 0.48
SECONDARY
Change in Eating Self-efficacy at Week 72
6.5; 1.7 0.16
SECONDARY
Change in Eating Self-efficacy at Week 46
5.8; -1.0 0.045 sig
SECONDARY
Change in Eating Self-efficacy at Week 20
12.3; 8.6 0.27
SECONDARY
Change in Triglycerides at Week 72
-9.9; -13.7 0.72
SECONDARY
Change in Triglycerides at Week 20
-10.9; -7.7 0.67
SECONDARY
Change in Blood Pressure at Week 72
-5.0; -5.6; -1.9; -2.0 0.80
SECONDARY
Change in Blood Pressure Week 20
-9.7; -5.4; -3.5; -3.6 0.07
SECONDARY
Change in Weight Bias Internalization Scale Score at Week 72
-1.7; -1.5 0.30
SECONDARY
Change in Weight Bias Internalization Scale Score at Week 46
-1.5; -1.4 0.67
SECONDARY
Change in Weight Bias Internalization Scale Score at Week 20
-1.4; -1.2 0.45
SECONDARY
"Remission" of Elevated Weight Bias Internalization at Week 72
28; 26 0.38
SECONDARY
"Remission" of Elevated Weight Bias Internalization at Week 46
24; 25 0.95
SECONDARY
"Remission" of Elevated Weight Bias Internalization at Week 20
25; 26 0.99
SECONDARY
Change in Weight Self-stigma Scores at Week 72
-9.7; -6.7; -5.0; -3.8; -4.7; -2.9 0.06
SECONDARY
Change in Weight Self-stigma Scores at Week 46
-8.5; -5.5; -4.0; -2.8; -4.5; -2.7 0.05
SECONDARY
Change in Weight Self-stigma Scores at Week 20
-8.2; -5.5; -4.6; -3.2; -3.6; -2.3 0.07
SECONDARY
Treatment Acceptability at Week 20
6.4; 5.8; 6.1; 5.9; 6.1; 4.6 0.04 sig
SECONDARY
Treatment Acceptability at Week 72
6.1; 5.8; 6.0; 5.7; 5.9; 4.1 0.24

Summary

This is a randomized controlled trial to test the effects on long-term weight loss of a novel stigma-reduction intervention combined with standard BWL treatment, as compared to BWL alone. Participants will be a total of 104 men and women seeking weight loss, ages 18 years and older, with a body mass index (BMI) of 30 kg/m2 or above (or 27 kg/m2 or above with an obesity-related comorbidity), a history of experiencing weight bias, and elevated levels of WBI. Participants will attend a screening visit in which they will complete a behavioral evaluation with a psychologist and a medical history that will be reviewed by a nurse practitioner or physician. Questionnaires assessing experiences and internalization of weight bias, with confirmation by interviewer assessment during the behavioral evaluation, will be used to determine whether participants meet criteria for having high levels of WBI. Eligible consenting participants will be randomly assigned to the standard BWL intervention (n = 52) or the stigma + BWL intervention (n = 52). All participants will attend weekly, 90-minute group meetings for 20 weeks (20 visits). In the stigma + BWL treatment group, 60 minutes will be devoted to BWL and 30 minutes to weight stigma. In the standard BWL treatment group, the additional 30 minutes will be devoted to sharing recipes and food preparation tips. Following 20 weeks of weight loss treatment, participants will attend group meetings focused on weight loss maintenance, monthly from weeks 21-46 (6 visits), and every-other-month from weeks 47-72 (3 visits). Maintenance sessions in the stigma + BWL group will continue to incorporate discussion of WBI and stigma-related barriers to physical activity. Assessments - which include questionnaires, blood draws, and measurements of body weight and physical activity - will occur at baseline and weeks 20, 46 (no blood draw this week), and 72. Weight will be measured at every group meeting for clinical purposes.

Eligibility Criteria

Inclusion Criteria

  • Eligible participants will be men and women ages 18 years and older.
  • Participants must have obesity, defined as a BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 with an obesity-related comorbidity.

o Obesity-related comorbidities (which confer added CVD risk) will include:

  • coronary heart disease;
  • other atherosclerotic disease;
  • sleep apnea;
  • hypercholesteremia (i.e., high cholesterol, as diagnosed by doctor and/or if taking medication to lower cholesterol);
  • and components of the metabolic syndrome, including hypertension (SBP ≥130, DBP ≥80 mm Hg, diagnosed by doctor and/or if taking anti-hypertensive medication); fasting blood glucose of 100-125 mg/dL (or prediabetes, diagnosed by doctor),; low HDL cholesterol ( 150 mg/dL, i.e., dyslipidemia diagnosed by doctor or taking medication to treat dyslipidemia), or elevated waist circumference (≥40 in for men, ≥35 in for women),.
  • Eligible participants must also report a history of experiencing weight bias as assessed by self-report questionnaire and in-person interview, and have elevated levels of WBI as indicated by an average score of 4 (midpoint) or above on the Weight Bias Internalization Scale (WBIS) and by in-person interview.
  • Participants must be seeking weight loss.
  • If currently taking medications, dosages must be stable for at least 3 months.
  • Participants will be eligible to participate if they exhibit mild to moderate severity of depression, anxiety, or binge eating disorder, as determined by the behavioral evaluation and the screening measures (Beck Depression Inventory-II and Questionnaire for Eating and Weight Patterns; see below for details). Elevated WBIS scores are often associated with these variables.
  • Participants taking anti-depressant medication will be eligible if their dose has been stable for a minimum of 3 months.

Eligible female patients will be:

  • non-pregnant and non-lactating
  • surgically sterile or postmenopausal, or they will agree to continue to use a method of birth control during the study

Participants must:

  • have a PCP who is responsible for providing routine care
  • have reliable telephone service and/or email access with which to be in contact with the study team
  • understand and be willing to comply with all study-related procedures and agree to participate in the study by giving written informed consent

Exclusion Criteria

Applicants will be excluded if they have:

  • a diagnosis of type I or II diabetes (for type II diabetes, blood glucose ≥126 mg/dL or A1C ≥6.5);
  • uncontrolled hypertension (blood pressure ≥ 160/100 mm Hg);
  • experienced a cardiovascular event (e.g., stroke, myocardial infarction) in the last 12 months;
  • lost and maintained ≥ 5% of their initial weight in the last 3 months or ≥ 10% in the past 2 years;
  • or have participated in individual or group psychotherapy related to weight in the last 3 months (due to the potentially confounding effects of receiving a simultaneous cognitive-behavioral intervention).

o Participants who have recently received or are currently receiving therapy for a pre-existing mental health issue unrelated to weight (e.g., psychotherapy for depression or anxiety, or marriage, grief, or career counseling) may be eligible if the therapy is deemed by the Principal Investigator to be unlikely to affect weight, eating habits, or physical activity.

  • Applicants with severe symptoms of mood (BDI-II score ≥ 29), anxiety, or binge eating disorder, and any severity of thought or substance use disorders will not be accepted into the study, as these symptoms may interfere with individuals' ability to adhere to a weight loss program.

o Clinician judgment will be used to determine severity of mood disorder symptoms independent from obesity-related concerns and complications (e.g., fatigue), and decisions about applicants' eligibility based on psychiatric symptoms will fall within the Principal Investigator's discretion.

  • Individuals with bulimia nervosa will not be eligible to partici
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03704064). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search